Background
==========

In patients with pulmonary disease it is often challenging to distinguish exacerbated pulmonary disease from congestive heart failure (CHF). B-type natriuretic peptide (BNP) levels are significantly higher in CHF as compared with exacerbated pulmonary disease.

Methods
=======

This study evaluated the predefined subgroup of 226 patients with a history of pulmonary disease included in a prospective randomized controlled trial of BNP testing for the emergency diagnosis of acute dyspnea. Patients were randomly assigned to a diagnostic strategy with (*n*= 119, BNP group) or without (*n*= 107, clinical group) the use of BNP levels provided by a rapid bedside assay. The time to discharge and the total cost of treatment were recorded as the primary endpoints.

Results
=======

Baseline demographic and clinical characteristics were well matched between groups. Comorbidity was extensive, including coronary artery disease and hypertension in one-half of the patients. The primary discharge diagnosis was CHF and exacerbated obstructive pulmonary disease in 39% and 33%, respectively. The use of BNP levels significantly reduced the need for hospital admission (81% vs 91%, *P*= 0.034). The median time to discharge was 9.0 days in the BNP group as compared with 12.0 days (*P*= 0.001) in the clinical group. The total cost of treatment was \$5764 (95% confidence interval, 4450--7078) in the BNP group as compared with \$7665 (95% confidence interval, 6448--8882; *P*= 0.038) in the clinical group (Fig. [1](#F1){ref-type="fig"}). Inhospital mortality was 8% in both groups.
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Conclusion
==========

Used in conjunction with other clinical information, rapid measurement of BNP reduced the time to discharge and total treatment cost of patients with a history of pulmonary disease presenting with acute dyspnea.
